Stifel lowered the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$17 from C$19 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals Q3 2024 Results: Growth and Acquisitions
- Cipher Pharmaceuticals’ Revenue Soars After Natroba Acquisition
- CPHRF Earnings this Week: How Will it Perform?
- Cipher Pharmaceuticals Announces Q3 2024 Financial Results
- Cipher Pharmaceuticals price target raised to C$19 from C$17 at Stifel